{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiedm5okwwhhdwnxxmpxd7x3al6fgvrp2yrmulxu37qtqvmosk4kry",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgware6u3ki2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/03/12/fda-telehealth-lilly-obesity-compounding-pbm-glp1-abortion/?utm_campaign=rss",
  "publishedAt": "2026-03-12T13:23:58.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "Medical groups affiliated with telehealth companies the FDA warned about marketing of compounded weight loss drugs may be under the microscope, too",
  "title": "STAT+: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more",
  "updatedAt": "2026-03-12T13:24:02.000Z"
}